US 12,064,407 B2
Endogenous retrovirus-k (ERVK) encodes an alternate envelope protein
Renée Douville, Winnipeg (CA); and Mamneet Gurm, Winnipeg (CA)
Assigned to UNIVERSITY OF WINNIPEG, Winnipeg (CA)
Appl. No. 16/756,947
Filed by University of Manitoba, Winnipeg (CA)
PCT Filed Oct. 17, 2018, PCT No. PCT/CA2018/051306
§ 371(c)(1), (2) Date Apr. 17, 2020,
PCT Pub. No. WO2019/075562, PCT Pub. Date Apr. 25, 2019.
Claims priority of provisional application 62/573,290, filed on Oct. 17, 2017.
Prior Publication US 2023/0064896 A1, Mar. 2, 2023
Int. Cl. A61K 31/192 (2006.01); A61K 31/352 (2006.01); A61K 31/40 (2006.01); A61K 31/56 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 31/352 (2013.01); A61K 31/40 (2013.01); A61K 31/56 (2013.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01)] 9 Claims
 
1. A method for treating or preventing a condition or disorder associated with ω-conotoxin-like protein(CTXLP) in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of active agent optionally in a physiological carrier, or a pharmaceutically acceptable salt thereof, wherein the active agent blocks or inhibits CTXLP activity and/or CTXLP associated pathology, wherein said condition or disorder is an infectious disease or cancer,
wherein said active agent comprises a Michael acceptor electrophile (MAE), gambogic acid, celastrol, a small molecule inhibitor of HIV Tat, curcumin, rosmarinic acid, 15-deoxy-Δ(12,14)-prostaglandin J(2) (15d-PGJ(2), a cyclopentenone prostaglandin (CyPG), N-acetylcysteine amide (NACA), or D-penicillamine; a sulfhydryl compound with chelating properties, N-(2-Mercapto-propionyl)-glycin (MPG), 2,3-Dimercapto-propanol (DMP), 2,3-Dimercapto-propane-sulfonic acid (DMPS), Nitric oxide (NO), or a sulphated polysaccharide; or a Thioredoxin reductase 1 (TRR1) inhibitor, B5 (curcumin analog), a small molecule or antibody reversing CTXLP blockade on oligodendrocyte precursor cell maturation and oligodendrocyte myelination, clemastine fumarate, a small molecule enhancer of expression or activity of CaV2.2 or its calcium channel associated transcription regulator (CaV2.2 CCAT) of expression or activity, EGTA, or glutamate.